Enprostil, a prostaglandin E<sub><i>2</i></sub> analogue, in the treatment of duodenal ulcer; a multicentre' comparison with cimetidine

Jazrawi, R. P.; Northfield, T. C.; Reed, P I; Cockel, R.; Schiller, K. F. R.; Barker, Eva

doi:10.1111/j.1365-2036.1988.tb00708.x

Cited by 3 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Enprostil is a synthetic E 2 dehydro‐prostaglandin withgastric antisecretory and cytoprotective activity 1‐4 . Early clinical studies indicated that enprostil can heal both gastric and duodenal ulcers, with minimal adverse effects, within four to six weeks of the initiation of treatment 5‐9 .…”

Section: Introductionmentioning

confidence: 99%

Enprostil, a prostaglandin E₂ analogue, in the treatment of gastric ulcer — a multicentre comparison with pirenzepine

Reed

Jazrawi

Northfield

et al. 1990

Int J Clinical Practice

View full text Add to dashboard Cite

SummaryIn a double‐blind, multicentre study 77 patients with benign gastric ulcer were randomly allocated to treatment with either enprostil 35 μg bd or pirenzepine 50 mg bd. After four weeks of treatment 13/26 (50 per cent) of evaluable enprostil‐treated patients and 9/30 (30 per cent) of evaluable pirenzepine‐treated patients were healed. Corresponding healing figures after eight weeks were 20/25 (80 per cent) and 25/31 (81 percent). Both drugs rapidly reduced the severity of ulcer pain and the need for antacid use. No statistically significant differences were detected between the treatments with respect to healing rate or symptom control. Adverse events were reported by eight patients taking enprostil and by 17 patients taking pirenzepine. Two patients withdrew from each treatment group because of adverse events. None of these was serious.In conclusion, enprostil and pirenzepine were equally effective in healing gastric ulcers and no statistically significant differences in safety and efficacy were detected. There was a tendency for earlier healing and fewer side effects in the enprostil‐treated patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Enprostil, a prostaglandin E₂ analogue, in the treatment of gastric ulcer — a multicentre comparison with pirenzepine

Reed

Jazrawi

Northfield

et al. 1990

Int J Clinical Practice

View full text Add to dashboard Cite

show abstract

A comparison of two prostaglandin analogues (enprostil vs misoprostol) in the treatment of acute duodenal ulcer disease

Ching

Lam

1995

J Gastroenterol

View full text Add to dashboard Cite

We conducted a clinical trial to compare the efficacy and safety profile of two prostaglandin analogues, enprostil (35 micrograms twice daily) and misoprostol (200 micrograms four times daily) in the treatment of acute duodenal ulcers in 214 patients. The two agents healed approximately 80% and in excess of 90% of duodenal ulcers after 4 and 6 weeks' therapy, respectively. There was a significantly lower ulcer healing rate in both treatment groups in smokers compared with non-smokers (P < 0.05). However, daytime and nighttime ulcer pain relief was achieved in fewer than 50% of patients by either agent. Diarrhea, which occurred in more than 40% of patients, was the predominant side effect, and occurred mainly during the first 2 weeks of therapy with either agent. Nevertheless, this side effect was mild and self-limiting in the majority of patients. Both agents were found to be safe and well tolerated by the majority of patients. We conclude that these prostaglandin analogues are safe and effective duodenal ulcer healing agents. Furthermore, there was very little difference between enprostil and misoprostol. The limiting factors, however, for their routine use as ulcer healing agents are their low efficacy with regard to ulcer pain relief and the high incidence of diarrhea.

show abstract

A comparison of low‐dose maintenance treatment with enprostil against ranitidine in the prevention of duodenal ulcer recurrence

Bardhan

Morris²,

Hinchliffe³

et al. 1989

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SUMMARY Enprostil, a prostaglandin E2 analogue, is effective in healing acute duodenal ulcer but its value in preventing recurrence, when given daily for maintenance therapy, is uncertain. In this three‐centre study we compared enprostil and ranitidine maintenance therapy; the latter is known to reduce duodenal ulcer relapse rates. Patients whose duodenal ulcers had been healed by treatment with an H2‐receptor antagonist were randomized to receive single‐blind treatment with either 35 μg enprostil (n = 64) or 150 mg ranitidine (n = 64) at bedtime for periods of up to 1 year. Endoscopy was routinely performed at 3 months at one centre, and at 6 and 12 months at all three centres, or whenever ulcer symptoms recurred. Clinical assessment and laboratory investigations were performed every 3 months. Relapse, defined as recurrent ulcer with or without pain, or erosions with pain, was significantly greater in patients on enprostil, the comparative rates at 3, 6 and 12 months were: enprostil 23, 31 and 36% ranitidine 6, 12 and 17% (P= 0.013; P= 0.03 and P= 0.03, respectively).

show abstract

Enprostil, a prostaglandin E₂ analogue, in the treatment of duodenal ulcer; a multicentre' comparison with cimetidine

Cited by 3 publications

References 5 publications

Enprostil, a prostaglandin E₂ analogue, in the treatment of gastric ulcer — a multicentre comparison with pirenzepine

Enprostil, a prostaglandin E₂ analogue, in the treatment of gastric ulcer — a multicentre comparison with pirenzepine

A comparison of two prostaglandin analogues (enprostil vs misoprostol) in the treatment of acute duodenal ulcer disease

A comparison of low‐dose maintenance treatment with enprostil against ranitidine in the prevention of duodenal ulcer recurrence

Contact Info

Product

Resources

About

Enprostil, a prostaglandin E2 analogue, in the treatment of duodenal ulcer; a multicentre' comparison with cimetidine

Cited by 3 publications

References 5 publications

Enprostil, a prostaglandin E2 analogue, in the treatment of gastric ulcer — a multicentre comparison with pirenzepine

Enprostil, a prostaglandin E2 analogue, in the treatment of gastric ulcer — a multicentre comparison with pirenzepine

A comparison of two prostaglandin analogues (enprostil vs misoprostol) in the treatment of acute duodenal ulcer disease

A comparison of low‐dose maintenance treatment with enprostil against ranitidine in the prevention of duodenal ulcer recurrence

Contact Info

Product

Resources

About

Enprostil, a prostaglandin E₂ analogue, in the treatment of duodenal ulcer; a multicentre' comparison with cimetidine

Enprostil, a prostaglandin E₂ analogue, in the treatment of gastric ulcer — a multicentre comparison with pirenzepine

Enprostil, a prostaglandin E₂ analogue, in the treatment of gastric ulcer — a multicentre comparison with pirenzepine